

Technology Advisory Committee B Interests Register
Ofatumumab for treating relapsing multiple sclerosis [ID1677]
Publication Date: 19/05/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Nicholas Latimer	TA Committee B Member	Direct - financial	Received payment from Merck Serono to present methods for modelling treatment sequences at ISPOR Webinar in May 2020. The presentation was unrelated to any specific drug/disease area.	NA	08/01/2021	NA	It was agreed that this declaration would not prevent Dr Latimer from participating in this section of the meeting
Dr Eli Silber	Clinical Expert	Non-financial professional & personal interest	Trialist in a study sponsored by Novartis until February 2019.	NA	19/06/2020	NA	It was agreed that this declaration would not prevent Dr Silber from providing expert advice to the committee.
Dr Eli Silber	Clinical Expert	Indirect interest	Institution received financial support from Novartis. Dr Silber did not receive any direct benefit from this support.	NA	04/02/2021	NA	It was agreed that this declaration would not prevent Dr Silber from providing expert advice to the committee.
Dr Helen Ford	Clinical Expert	Direct – financial	Honoraria for advisory boards, speaker fees or support to attend educational meetings from Biogen (22/01/2020) and Novartis (28/01/2020), as well as for several other pharmaceuticals dating back more than 12 months ago.	NA	22/06/2020	NA	It was agreed that these declarations would not prevent Dr Ford from providing expert advice to the committee.

